PRINCETON, N.J., Aug. 17, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Israeli Ministry of Health (MoH) has approved national reimbursement for CytoSorb® in certain cardiac surgery indications that is expected to take effect in 2023.
Pizza Hut Canada Tests Robotic Doorstep Delivery In Vancouver
Yum! Brands Inc (NYSE:YUM) owned Pizza Hut Canada is testing its new robot delivery service. The national chain is partnering with…
